scholarly journals Impact of cyclophosphamide on long-term reduction in sperm count in men treated with combination chemotherapy for ewing and soft tissue sarcomas

Cancer ◽  
1992 ◽  
Vol 70 (11) ◽  
pp. 2703-2712 ◽  
Author(s):  
M. L. Meistrich ◽  
G. Wilson ◽  
B. W. Brown ◽  
M. F. Da Cunha ◽  
L. I. Lipshultz
Keyword(s):  
Soft Tissue ◽  
Combination Chemotherapy ◽  
Sperm Count ◽  
Soft Tissue Sarcomas

scholarly journals Efficacy of combination-chemotherapy with pirarubicin, ifosfamide, and etoposide for soft tissue sarcoma: a single-institution retrospective analysis

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Shiro Saito ◽  
Hisaki Aiba ◽  
Satoshi Yamada ◽  
Hideki Okamoto ◽  
Katsuhiro Hayashi ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Adverse Events ◽  
Combination Chemotherapy ◽  
Progressive Disease ◽  
Treatment Phase ◽  
Hematological Toxicity ◽  
Single Institution ◽  
Grade 3

Abstract Background The standard chemotherapy regimens for soft tissue sarcoma are doxorubicin-based. This retrospective study aimed to assess the efficacy and safety of pirarubicin, ifosfamide, and etoposide combination therapy for patients with this disease. Methods Between 2008 and 2017, 25 patients with soft tissue sarcoma were treated with pirarubicin (30 mg/m2, 2 days), ifosfamide (2 g/m2, 5 days), and etoposide (100 mg/m2, 3 days) every 3 weeks. The primary endpoint was overall response, and the secondary endpoint was adverse events of this regimen. Results Responses to this regimen according to RECIST criteria were partial response (n = 9, 36%), stable disease (n = 9, 36%) and progressive disease (n = 7, 28%). During the treatment phase, frequent grade 3 or worse adverse events were hematological toxicities including white blood cell decreases (96%), febrile neutropenia (68%), anemia (68%), and platelet count decreases (48%). No long-term adverse events were reported during the study period. Conclusion This regimen was comparable to previously published doxorubicin-based combination chemotherapy in terms of response rate. Although there were no long-lasting adverse events, based on our results, severe hematological toxicity should be considered.

Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas

2009 ◽  
Vol 20 (1) ◽  
pp. 15-20 ◽  
Author(s):  
Tal Grenader ◽  
Anthony Goldberg ◽  
Irit Hadas-Halperin ◽  
Alberto Gabizon
Keyword(s):  
Soft Tissue ◽  
Liposomal Doxorubicin ◽  
Soft Tissue Sarcomas ◽  
Pegylated Liposomal Doxorubicin ◽  
Term Response

Extended ray resection for sarcoma of the hand: long-term survival and functional results

2019 ◽  
Vol 45 (2) ◽  
pp. 160-166 ◽  
Author(s):  
Farhad Farzaliyev ◽  
Hans-Ulrich Steinau ◽  
Halil-Ibrahim Karadag ◽  
Alexander Touma ◽  
Lars Erik Podleska
Keyword(s):  
Soft Tissue ◽  
Survival Rates ◽  
Soft Tissue Sarcomas ◽  
Functional Results ◽  
Contralateral Side ◽  
Level Of Evidence ◽  
Term Survival ◽  
Kaplan Meier

In this retrospective study, we analysed the long-term oncological and functional results after extended ray resection for sarcoma of the hand. Recurrence-free and overall survivals were calculated using the Kaplan–Meier method. The function of the operated hand was assessed with the Michigan Hand Questionnaire and compared with the contralateral side. Extended ray resection was performed in 25 out of 168 consecutive patients with soft-tissue and bony sarcomas of the hand. The overall 5- and 10-year, disease-specific survival rates were 86% and 81%, respectively. Local recurrences were observed in two patients. The Michigan Hand Questionnaire score for the affected hand at follow-up in nine patients was 82 points versus 95 for the healthy contralateral hands. We conclude that extended ray resection of osseous sarcomas breaking through the bone into the soft tissue or for soft tissue sarcomas invading bone is a preferable alternative to hand ablation when excision can be achieved with tumour-free margins. Level of evidence: III

scholarly journals Long-Term Response after 94 Cycles of Trabectedin in a Patient with Metastatic Leiomyosarcoma of the Lower Extremity

2020 ◽  
Vol 13 (1) ◽  
pp. 113-119 ◽  
Author(s):  
Magda Cordeiro ◽  
José Manuel Casanova ◽  
Joana Rodrigues ◽  
João Freitas ◽  
Ruben Fonseca ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Soft Tissue ◽  
Lower Extremity ◽  
Disease Progression ◽  
Stable Disease ◽  
Case Reports ◽  
Soft Tissue Sarcomas ◽  
Term Therapy

Leiomyosarcomas of the lower extremity are extremely rare disorders and account for 10–15% of limb soft tissue sarcomas. These tumours have poor prognosis and even in early stages, patients persist at high risk for local and distant relapse; consequently, the treatment of advanced leiomyosarcoma of the lower extremity embodies a substantial defy. We present the case of a 73-year-old man diagnosed with metastatic lower extremity leiomyosarcoma of the hallux soft tissue, and with bone, lung and lymph node metastasis. After core needle biopsy confirmation of high-grade fusocellular sarcoma, the patient underwent surgery of the primary tumour and received anthracycline-based chemotherapy. However, after a 7-month progression-free survival period, a CT revealed lung disease progression. Sequentially, the patient was treated with trabectedin (Yondelis®) at a dose of 1.5 mg/m2 resulting in complete remission of the lung metastasis and stable disease of the remaining lesions after 26 months of treatment. Afterwards, the patient started on maintenance therapy with trabectedin, resulting in long-lasting stable disease, as he was able to receive 94 cycles with very acceptable quality of life. Finally, in March 2019, the patient died of community-acquired pneumonia without objective progression disease. This clinical case reports the first patient ever treated with 94 cycles of trabectedin. Our results additionally confirm that trabectedin wields relevant oncostatic benefits with a manageable safety profile and without cumulative toxicities. Trabectedin properties enable a maintenance long-term therapy (until disease progression or unbearable toxicity), with a high impact on survival and with a preserved quality of life.

Re-excision after unplanned excision of soft tissue sarcomas: Long-term results

2020 ◽  
Vol 34 ◽  
pp. 212-217
Author(s):  
Guido Scoccianti ◽  
Matteo Innocenti ◽  
Filippo Frenos ◽  
Francesco Muratori ◽  
Federico Sacchetti ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Long Term Results ◽  
Unplanned Excision

scholarly journals A maxillary ameloblastic fibrosarcoma tumor: a rare case report from Syria

2020 ◽  
Vol 2020 (8) ◽  
Author(s):  
Amjad Soltany ◽  
Ghazal Asaad ◽  
Rami Daher ◽  
Mouhannad Dayoub ◽  
Ali Khalil ◽  
...  
Keyword(s):  
Case Report ◽  
Soft Tissue ◽  
Rare Case ◽  
Soft Tissue Sarcomas ◽  
Surgical Excision ◽  
Low Grade ◽  
Rare Case Report ◽  
Ameloblastic Fibrosarcoma ◽  
The Right

Abstract Ameloblastic fibrosarcoma (AFS) is a rare, aggressive malignant odontogenic tumor. AFS is seen most frequently in second and third decades of life. We are reporting a case of a low grade AFS in a 21-year-old male complaining of a painless swelling in the right side of the maxilla. The patient was treated with surgical excision followed by radiotherapy, which is considered the most effective approach for most of soft tissue sarcomas. AFS has a high-reported recurrence rate (up to 37%); therefore, long-term surveillance for recurrence is crucial.

scholarly journals Long-term recurrence of soft tissue sarcomas: Prognostic factors and implications for prolonged follow-up

Cancer ◽  
2014 ◽  
Vol 120 (19) ◽  
pp. 3003-3006 ◽  
Author(s):  
Maud Toulmonde ◽  
Axel Le Cesne ◽  
Jean Mendiboure ◽  
Jean-Yves Blay ◽  
Sophie Piperno-Neumann ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Soft Tissue ◽  
Soft Tissue Sarcomas

Hematopoietic Stem Cell Transplantation and Secondary Primary Malignancies in Taiwan

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 4219-4219 ◽  
Author(s):  
Chia-Jen Liu ◽  
Kuo-Wei Chen ◽  
Yu-Wen Hu ◽  
Ying-Chung Hong ◽  
Yu-Chung Huang ◽  
...  
Keyword(s):  
Stem Cell ◽  
Soft Tissue ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Hematological Malignancies ◽  
Soft Tissue Sarcomas ◽  
Cancer Development ◽  
Hematopoietic Stem ◽  
Long Term Survivors

Abstract Abstract 4219 Objectives Hematopoietic stem cell transplantation (HSCT) is a curative strategy for many hematological disorders. The improvement of HSCT may lead to longer overall survival of patients with catastrophic illness and the risk of secondary cancer development become an emerging issue in long-term survivors. Patients and Methods We conducted a nationwide population-based study of 1,881 patients with hematologic diseases undergoing HSCT between January, 1997 and January, 2007 using Taiwan's National Health Insurance Research database. Performing HSCT to treat non-hematological diseases were excluded. All patients were followed until solid cancer development, death, or the end of 2010. We did not put hematological malignancies as endpoint because solid tumors and hematological malignancies might have different carcinogensis mechanism. We used standardized incidence ratios (SIRs) to compare patterns of cancer incidence in patients with those of the general population. Multivariate analysis was undertaken using Cox proportional-hazards regression using a forward selection, likelihood ratio model to identify independent predictors of cancer development among patients after HSCT. Results We observed a total of 8,753.87 person-years in this study. Patients received HSCT had a significant increased risk of developing any kind of cancer (SIR 1.77, 95% confidence interval [CI] 1.15 – 2.62; p = 0.011). Specifically, patients after HSCT had increased cancer incidence of head and neck cancer (SIR 3.96, 95% CI 1.90 – 7.29; p < 0.001) and bone and soft tissue sarcomas (SIR 10.08, 95% CI 1.22 – 36.42; p = 0.035). In subgroup analyses, cancers were more likely to develop in patients aged 0 – 19 years (SIR 22.31, 95% CI 4.60 – 65.20; p < 0.001), and those who survived more than 5 years after HSCT (SIR 3.30, 95% CI 1.96 – 5.22; p < 0.001). Conclusion Our study demonstrates an increased incidence of cancer development in patients after HSCT, especially malignancies of head and neck and also bone and soft tissue sarcomas. Patients aged 0 – 19 years and those survived more than 5 years after HSCT have a higher incidence of developing cancer comparing to normal population. HSCT long-term survivors should therefore be monitored more carefully for cancer development and targeted with preventive intervention strategies. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document